Five FDA decisions to watch before the year ends

Tracker/Cross-border deals

Drugs discovered in China are reshaping dealmaking. Track the licensing agreements here.

Western drugmakers have signed 37 licensing deals for China-originated medicines this year, already more than in all of 2025.

Updated Sept. 29, 2026·Deals

Sundari and Corvane widen alliance to find long-acting antibodies

The expanded agreement carries a $600 million upfront payment and adds four targets in inflammatory disease.

Sept. 27, 2026·Deals

Health department opens funding program to speed early-stage trials

Officials say they will back proposals that compress the time between a first human dose and proof of concept, and are weighing changes to the traditional phased system.

Sept. 26, 2026·Clinical Trials

Arden & Pryce trial revisions shake confidence in a new class of fibrosis drugs

The company confirmed a small number of liver-related safety events, including one death, though investigators have not determined whether the drug was responsible.

Sept. 24, 2026·Clinical Trials

FDA begins review of Nordlicht's multiple sclerosis pill

It is the first time the agency has accepted an application for a drug of this type in both relapsing and progressive forms of the disease.

Sept. 23, 2026·FDA

Gene editing

Tessaly sues two startups, alleging theft of gene editing trade secrets

The complaint says a former scientist took confidential designs and helped launch a competing rare disease program. Both defendants deny the claims.

Sept. 21, 2026·Gene Therapy

Marrow Peak falls on four-year data for its Huntington's gene therapy

Disease progression slowed by 41% compared with a matched external group, down from 60% at the three-year mark.

Sept. 19, 2026·Gene Therapy

Obesity drugs

Arden & Pryce to pay up to $2.4 billion for a once-weekly obesity pill

The agreement gives the drugmaker a challenger to market-leading injections as it tries to reassure investors about growth after 2030.

Sept. 17, 2026·Deals

Third round of Medicare price negotiations adds fifteen drugs, including the first physician-administered medicines

The list covers treatments that accounted for about $41 billion in spending last year. Negotiated prices take effect in 2028.

Sept. 16, 2026·Drug Pricing